Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vulval intraepithelial neoplasia: immune responses to human papillomavirus
2007-006761-32Phase 4Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2008
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imiquimod in vulvar intraepithelial neoplasia (VIN) (4 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Local and systemic immune responses to human papillomavirus in vulval intraepithelial neoplasia, Comparative HPV-specific immune responses across disease groups and 1 more. Status: unknown.
02
Drugs
imiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2007-006761-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006761-32.